Updated, longer follow-up data from the KRYSTAL-1 trial, recently presented on September 10, 2023, at the World Congress on Lung Cancer 2023 (WCLC 2023) in Singapore, confirmed durable clinical activity and benefit of adagrasib in advanced KRAS G12C-mutant NSCLC across patient groups, including those with CNS metastases and co-mutations (48). This evidence concerns the gene KRAS and lung carcinoma.